Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo | Latest News RSS feed

Bristolmyers Squibbs 2q Earnings Beat Street On Healthy Sales Of Its Blockbuster Cancer Drug Opdivo - Latest News


Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

Bristol-Myers Squibb Co (NYSE:BMY) reported second-quarter earnings Thursday that topped Wall Street estimates on strong sales of its blockbuster cancer drug Opdivo and blood thinner Eliquis. For the ... read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

Late Movers: Merck drops after downgrade from BMO Capital Markets

READ: Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda Bristol-Myers Squibb Co (NYSE:BMY) shares headed south as the drug company withdrew an application to the US Food ... read more

Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda

READ: Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo Shares in Merck traded flat, slightly down to US$63.84 in premarket trade. “Strong ... read more

Looking for another news?


Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

NEW YORK (Reuters) - U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on ... read more


Bristol-Myers beat on earnings thanks to sales of its drugs that use the immune system to treat cancer

NEW YORK (Reuters) - Bristol-Myers Squibb ... for blockbuster Opdivo as well as pressure from activist investors, also raised its expectations for its full-year earnings, reversing a cut to its ... read more

Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming

Revenue increased 10% year over year, while earnings soared by 38%. Bristol-Myers Squibb provided its ... Opdivo increased by 19% year over year to $290 million. The fastest growth, though, was ... read more

The day has come: Merck’s Keytruda surpasses Bristol-Myers Squibb’s Opdivo in Q2 sales

Merck & Co.’s blockbuster cancer drug Keytruda has delivered again in the second quarter, and this time, it has seized the PD-1/L1 crown from Bristol-Myers Squibb’s archrival, Opdivo ... Human Health, ... read more

Merck, Bristol-Myers profits rise on cancer drug sales

(Reuters) - Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings ... cancer treatments. Bristol-Myers pioneered cancer ... read more

3 Things to Really Like About Bristol-Myers Squibb's Q4 Earnings Results

The drugmaker also beat Wall Street estimates with its bottom-line result. BMS announced non-GAAP net earnings ... for Opdivo, which is on track to become the No. 2 best-selling cancer drug in the ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us